153 patents currently held
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.
The next term ends in Jan 2028. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
14
Ending by 2030
Jan 2028
Next term end
61
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2031 · High confidence
Also notable
Ends May 2032 · High confidence
Also notable
Ends Feb 2030 · High confidence
Also notable
Ends Dec 2035 · High confidence
Also notable
Ends Oct 2033 · High confidence
Also notable
Ends Mar 2034 · High confidence
Also notable
Ends Jan 2033 · High confidence
Also notable
Ends Mar 2035 · High confidence
Mutation Detection Assay
US 8,715,937
The most cited patent in this portfolio, cited by 107 later US patents, top 5% of utility patents granted in 2014 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Isolation of Nucleic Acids
US 9,169,511
Cited by 56 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.
Fecal Sample Processing and Analysis Comprising Detection of Blood
US 11,634,781
Cited by 8 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Compositions and Methods for Performing Methylation Detection Assays
US 10,011,878
Cited by 61 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Normalization of Polymerase Activity
US 9,212,392
Cited by 50 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Detecting Neoplasm
US 10,683,555
Cited by 12 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
Modification of DNA on Magnetic Beads
US 9,315,853
Cited by 32 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Detecting Colorectal Neoplasm
US 10,883,144
Cited by 10 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2035.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Detecting Colorectal Neoplasm (US 10,301,680) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 5 fees due Dec 13 to 27, 2026 · next Dec 13
- 2 fees due Jan 18 to 25, 2027 · next Jan 18
- 1 fee due Feb 20, 2027The maintenance fee for Detection of Lung Neoplasia by Analysis of Methylated DNA (US 10,385,406) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
- 3 fees due Mar 1 to 8, 2027 · next Mar 1
- 5 fees due Apr 8 to 30, 2027 · next Apr 8
- 6 fees due May 5 to 26, 2027 · next May 5
- 5 fees due Jun 15 to 30, 2027 · next Jun 15
- 1 fee due Jul 2, 2027The maintenance fee for Detecting Gastric Neoplasm (US 11,859,254) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Aug 13, 2027The maintenance fee for Treatment and Diagnosis of Parkinson's Disease Using Isolated and Enriched Populations of Biofluid-Derived Extracellular Vesicles (US 11,899,024) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
- 3 fees due Sep 22 to 30, 2027 · next Sep 22
- 5 fees due Oct 9 to 30, 2027 · next Oct 9
- 1 fee due Nov 12, 2027The maintenance fee for Multiplex Amplification Detection Assay II (US 10,648,025) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
- 6 of the patents on this record were granted since Aug 23, 2026
What they patent
The largest of its 61 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Removal of PCR Inhibitors | 15 in force | to Dec 2032 |
| Mutation Detection Assay | 9 in force | to Jan 2032 |
| Multiplexed Kras Mutation Detection Assay | 6 in force | to Feb 2033 |
| Normalization of Polymerase Activity | 5 in force | to Feb 2034 |
| Sample Collection Device | 5 in force | to Jan 2034 |
| Real Time Cleavage Assay | 5 in force | to Oct 2031 |
| Methods for Detecting Epigenetic Modifications | 5 in force | to Jun 2030 |
| Detecting Gastric Neoplasm | 4 in force | to Nov 2036 |
| Detecting Neoplasm | 4 in force | to Nov 2035 |
| Digital Sequence Analysis of DNA Methylation | 4 in force | to Jan 2034 |
| Modification of DNA on Magnetic Beads | 4 in force | to Jan 2033 |
| Fecal Sample Processing and Analysis Comprising Detection of Blood | 4 in force | to Jul 2032 |
| Sample Collector Device | 3 in force | to Sep 2041 |
| Method for Stabilizing Hemoglobin and Reagents for Performing the Same | 3 in force | to Apr 2040 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,982,308 | Methods for Amplifying DNA from the Promoter of the NDRG4 Gene DNA Obtained from a Fecal Sample In force · High confidence | In force | High confidence | |
| US 10,808,286 | Methods for Detecting Epigenetic Modifications In force · High confidence | In force | High confidence | |
| US 11,149,317 | Methods for Detecting Epigenetic Modifications In force · High confidence | In force | High confidence | |
| US 12,215,389 | Compositions for Detecting Epigenetic Modifications In force · High confidence | In force | High confidence | |
| US 11,634,781 | Fecal Sample Processing and Analysis Comprising Detection of Blood In force · High confidence | In force | High confidence | |
| US 11,970,746 | Fecal Sample Processing and Analysis Comprising Detection of Blood In force · High confidence | In force | High confidence | |
| US 11,987,848 | Fecal Sample Processing and Analysis Comprising Detection of Blood In force · High confidence | In force | High confidence | |
| US 8,969,046 | Methods for Detecting Epigenetic Modifications In force · High confidence | In force | High confidence | |
| US 9,024,006 | Mutation Detection Assay In force · High confidence | In force | High confidence | |
| US 9,121,071 | Mutation Detection Assay In force · High confidence | In force | High confidence |
Also on record, not counted in the 153: 7 patents in force now held by others · 21 patents ended · 55 applications pending · 60 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.